No Data
The concept of contract research organizations has generally risen, wuxi bio (02269) increased by 7.48%, and institutions indicate that CRO/CDMO might gradually emerge from a notable turning point next year.
Jingu Finance | The contract research organizations concept saw widespread gains, with wuxi bio (02269) rising by 7.48%, wuxi apptec (02359) up by 6.12%, pharmaron (03759) increasing by 2.8%, genscript bio (01548) gaining 1.87%, and asymchem laboratories (06821) climbing by 1.44%. According to research reports from zhongtai, at the beginning of November, the pharmaceutical industry, which was at a low point, experienced a strong rebound, followed by fluctuations and adjustments with the large cap. Looking within the sector, catalyzed by policies such as the advance payment for medical insurance and the release of the medical insurance catalog, the pharmaceutical commerce and innovative drugs sub-sectors both performed well. The medical insurance policy's
Hong Kong stocks are showing some unusual movements | Most stocks related to the concept of CRO are trending upwards, with expectations of improvement in investment and financing on the margin. Geopolitical games are yet to unfold.
Many concept stocks in the CRO sector have risen. As of the time of publication, Wuxi Bio (02269) rose by 4.77% to HK$12.64; Wuxi Apptec (02359) rose by 3.47% to HK$50.75; and Genscript Bio (01548) rose by 2.8% to HK$11.
Market bullish stimulus boosts Hong Kong pharmaceutical stocks, with Genshuo Niaoyao rising over 14%.
① What bullish impacts does the medical insurance centralized procurement have on pharmaceutical companies? ② How do institutions view the subsequent development of pharmaceutical stocks?
China Securities Co.,Ltd.: In the 2024 version of the medical insurance catalog, the number of innovative drugs added has reached a new high, balancing 'ensuring basic coverage' and 'supporting genuine innovation'.
Overall situation of the 2024 medical insurance catalog: the results are stable, meeting expectations, with a record high in the number of new innovative drugs, reflecting a balanced consideration of fund safety, public medical needs, and support for innovation.
National medical insurance drug list unveiling soon! Keji Pharmaceutical's stock surged over 9%, leading the way in Hong Kong pharmaceutical stocks.
1. What is the importance of centralized procurement of pharmaceutical companies by medical insurance? 2. Which areas of products are expected to be included in the 2024 National Medical Insurance Drug Catalog?
Hong Kong stocks are moving differently | Most pharmaceutical stocks are rising as the results of the medical insurance negotiations are about to be revealed. Institutions indicate that the sector still has further room for recovery.
Most pharmaceutical stocks are rising, as of the deadline, Keji Pharmaceutical-B (02171) rose by 12.38%, to 7.71 Hong Kong dollars; innocare (09969) rose by 5.36%, to 6.49 Hong Kong dollars; Kainuo Ya-B (02162) rose by 4.3%, to 41.25 Hong Kong dollars.
Expand
102884128 : getting disappointed with this counter. every day drop.